Symphogen A/s

Forskningscenter Riso

Søren Kofoed Rasmussen

Lone Kjær Rasmussen

Torben Peter Frandsen

Katja Salomon Johansen

Peter Sejer Andersen

Johan Lantto

Lucilla Steinaa

Allan Jensen

John S Haurum

Anne Bondgaard Tolstrup

Margit Haahr Hansen

Søren Bregenholt Frederiksen

Mikael Blom Sørensen

The present invention provides a structural characterization platform that can be used to assess the stability of a polyclonal cell line during production, as well as batch-to-batch consistency of the final polyclonal products. The structural characterization platform is based on genetic analysis as well as protein characterization techniques that alone or in combination provides the necessary information to characterize the polyclonal cell line and final products. The collection of different homologous proteins to be analyzed with the platform techniques is for example a recombinant polyclonal antibody or a mixture of monoclonal antibodies.

Procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line

The invention relates to a method for manufacturing an anti-RhD recombinant polyclonal antibody composition (anti-RhD rpAb). The method comprises obtaining a collection of cells transfected with a library of anti-RhD antibody expression vectors, wherein each cell in the collection is capable of expressing from a VH and VL comprising nucleic acid segment, one member of the library, which encodes a distinct member of anti-RhD recombinant polyclonal antibody composition and which is located at the same site in the genome of individual cells in said collection. The cells are cultured under suitable conditions for expression of the recombinant polyclonal antibody, which is obtained from the cells or culture supernatant. The nucleic acid segments encoding the anti-RhD rpAb is introduced into the cells by transfection with a library of vectors for site-specific integration. The present method is suitable for manufacturing anti-RhD rpAb, thereby making available a superior replacement of plasma-derived prophylactic and therapeutic immunoglobulin products.

Anti-rhesus D recombinant polyclonal antibody

Disclosed is an anti-orthopoxvirus recombinant polyclonal antibody comprising distinct members which in union are capable of binding at least three orthopoxvirus related antigens, a pharmaceutical composition comprising the antibody, and a method for its production. Also disclosed is a polyclonal cell line capable of producing the recombinant polyclonal antibody as therapeutic methods utilizing the polyclonal antibody. Finally, the invention also pertains to a method for screening for useful Vand Vpairs useful when preparing the polyclonal antibody.

Anti-orthopoxvirus recombinant polyclonal antibody

The present invention relates to isolated polypeptides having phytase activity, recombinant DNA sequences encoding such polypeptides, methods of producing such polypeptides, and the use of the polypeptides in transgenic plants. The invention discloses polypeptides having affinity for the substrate phytate (1, 2, 3, 4, 5, 6 myo-inositol-hexakisphosphate, phytic acid), comprising an amino acid sequence as described by the invention. Furthermore, the invention discloses DNA fragments encoding the polypeptides, and cDNA fragments encoding the polypeptides. The polypeptides of the invention may, for example, be used as an additive in animal feeds, an additive in food for human consumption, or to extract proteins from rice bran. The invention also concerns a transgenic plant or part thereof, wherein the plant or part thereof has been genetically modified to comprise a polypeptide as defined by the invention.

Polynucleotides encoding phytase polypeptides

Growing community of inventors

Roskilde, Denmark

Søren Kofoed Rasmussen